论文部分内容阅读
目的探讨恩替卡韦治疗慢性乙型肝炎失代偿期肝硬化的效果。方法将37例乙肝后肝硬化失代偿期患者在患者知情同意基础上随机分成对照组17例,治疗组20例。对照组给予综合治疗,治疗组在综合治疗的基础上给予恩替卡韦0.5mg/d口服,疗程6个月,观察治疗前后患者临床症状、肝功能、HBV-DNA定量水平、腹水变化情况。结果治疗组在肝功好转、凝血功能恢复、HBV-DNA转阴率及腹水改善方面与对照组比较差异有统计学意义。治疗组治疗前后肝功能比较差异有显著性(P<0.05)。结论恩替卡韦可改善乙肝后肝硬化失代偿期患者的肝功能,阻止病情发展,提高生存质量,延长患者生存期。
Objective To investigate the effect of entecavir in the treatment of decompensated cirrhosis of chronic hepatitis B patients. Methods Thirty-seven patients with decompensated hepatitis B after liver cirrhosis were randomly divided into control group (n = 17) and treatment group (n = 20) on the basis of informed consent. The control group was given comprehensive treatment. The treatment group was given entecavir 0.5 mg / d orally for 6 months on the basis of comprehensive treatment. The clinical symptoms, liver function, HBV-DNA quantitative level and changes of ascites were observed before and after treatment. Results The treatment group had significant difference with the control group in improvement of liver function, recovery of coagulation, HBV-DNA negative rate and ascites improvement. The liver function of the treatment group before and after treatment was significantly different (P <0.05). Conclusion Entecavir can improve liver function in patients with decompensated hepatitis B, prevent the progression of the disease, improve the quality of life, and prolong the survival of patients.